 Donald Jensen
Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 31 | 2019 | 139 | 9.670 |
Why?
| | Hepatitis C, Chronic | 28 | 2019 | 84 | 8.580 |
Why?
| | Hepacivirus | 28 | 2019 | 74 | 6.780 |
Why?
| | Interferon-alpha | 20 | 2016 | 71 | 4.390 |
Why?
| | Ribavirin | 19 | 2016 | 32 | 4.380 |
Why?
| | Hepatitis C | 12 | 2016 | 68 | 3.980 |
Why?
| | Polyethylene Glycols | 17 | 2016 | 56 | 3.940 |
Why?
| | Drug Therapy, Combination | 17 | 2016 | 265 | 1.760 |
Why?
| | Protease Inhibitors | 4 | 2016 | 21 | 1.600 |
Why?
| | Proline | 7 | 2019 | 22 | 1.490 |
Why?
| | Sulfonamides | 6 | 2019 | 64 | 1.430 |
Why?
| | Recombinant Proteins | 20 | 2016 | 295 | 1.380 |
Why?
| | Gastroenterology | 4 | 2016 | 16 | 1.110 |
Why?
| | Oligopeptides | 2 | 2016 | 34 | 1.100 |
Why?
| | Interferons | 3 | 2015 | 15 | 1.070 |
Why?
| | Liver Transplantation | 4 | 2012 | 114 | 1.040 |
Why?
| | RNA, Viral | 13 | 2016 | 163 | 1.010 |
Why?
| | Genotype | 11 | 2016 | 423 | 0.870 |
Why?
| | Humans | 50 | 2019 | 31481 | 0.830 |
Why?
| | Quinoxalines | 1 | 2019 | 11 | 0.770 |
Why?
| | Benzimidazoles | 1 | 2019 | 15 | 0.760 |
Why?
| | Drug Design | 1 | 2019 | 34 | 0.750 |
Why?
| | Viral Nonstructural Proteins | 2 | 2016 | 9 | 0.720 |
Why?
| | Liver | 5 | 2016 | 214 | 0.700 |
Why?
| | Treatment Outcome | 15 | 2016 | 3910 | 0.660 |
Why?
| | Viral Load | 7 | 2016 | 213 | 0.630 |
Why?
| | Drug Approval | 2 | 2016 | 31 | 0.630 |
Why?
| | Drugs, Generic | 1 | 2016 | 4 | 0.620 |
Why?
| | Thiazoles | 1 | 2016 | 38 | 0.610 |
Why?
| | Benzothiadiazines | 1 | 2015 | 1 | 0.600 |
Why?
| | Liver Diseases | 2 | 2016 | 40 | 0.600 |
Why?
| | Quinolones | 1 | 2015 | 23 | 0.590 |
Why?
| | Serine Proteinase Inhibitors | 2 | 2012 | 3 | 0.570 |
Why?
| | Hepatitis B, Chronic | 1 | 2014 | 10 | 0.550 |
Why?
| | Coinfection | 1 | 2014 | 33 | 0.530 |
Why?
| | Editorial Policies | 1 | 2014 | 7 | 0.530 |
Why?
| | Journal Impact Factor | 1 | 2014 | 15 | 0.520 |
Why?
| | Kidney Transplantation | 2 | 2008 | 141 | 0.510 |
Why?
| | Time Factors | 7 | 2016 | 1902 | 0.500 |
Why?
| | Periodicals as Topic | 1 | 2014 | 46 | 0.490 |
Why?
| | Drug Monitoring | 1 | 2013 | 29 | 0.490 |
Why?
| | Middle Aged | 21 | 2016 | 11209 | 0.480 |
Why?
| | Monitoring, Immunologic | 1 | 2012 | 2 | 0.470 |
Why?
| | Interleukins | 1 | 2012 | 42 | 0.450 |
Why?
| | Graft Rejection | 1 | 2012 | 84 | 0.450 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 87 | 0.440 |
Why?
| | Adult | 19 | 2016 | 9779 | 0.430 |
Why?
| | Male | 23 | 2016 | 17583 | 0.420 |
Why?
| | Anemia | 2 | 2011 | 94 | 0.420 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 225 | 0.410 |
Why?
| | Lactams, Macrocyclic | 4 | 2019 | 10 | 0.410 |
Why?
| | Cyclopropanes | 4 | 2019 | 27 | 0.410 |
Why?
| | Drug Administration Schedule | 6 | 2016 | 257 | 0.400 |
Why?
| | Hepatitis B | 1 | 2010 | 19 | 0.390 |
Why?
| | Female | 22 | 2016 | 18253 | 0.390 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 462 | 0.370 |
Why?
| | Transaminases | 1 | 2008 | 9 | 0.360 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2016 | 375 | 0.360 |
Why?
| | Aminoisobutyric Acids | 2 | 2019 | 4 | 0.350 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2008 | 7 | 0.350 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2008 | 6 | 0.350 |
Why?
| | Leucine | 2 | 2019 | 18 | 0.350 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2008 | 3 | 0.350 |
Why?
| | Heart Transplantation | 1 | 2008 | 50 | 0.340 |
Why?
| | Retreatment | 4 | 2014 | 18 | 0.340 |
Why?
| | United States | 6 | 2016 | 2539 | 0.330 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 160 | 0.330 |
Why?
| | HIV Infections | 1 | 2014 | 951 | 0.320 |
Why?
| | Clinical Trials as Topic | 4 | 2012 | 378 | 0.320 |
Why?
| | Interferon Type I | 2 | 2003 | 20 | 0.300 |
Why?
| | Remission Induction | 3 | 2015 | 119 | 0.300 |
Why?
| | Treatment Failure | 4 | 2009 | 187 | 0.300 |
Why?
| | Lactams | 2 | 2015 | 6 | 0.290 |
Why?
| | Hospital Departments | 1 | 2005 | 9 | 0.290 |
Why?
| | Liver Cirrhosis | 2 | 2016 | 60 | 0.290 |
Why?
| | Logistic Models | 3 | 2016 | 479 | 0.280 |
Why?
| | Ritonavir | 2 | 2014 | 18 | 0.270 |
Why?
| | Hospital Costs | 1 | 2005 | 73 | 0.270 |
Why?
| | Nucleotidases | 1 | 2004 | 1 | 0.270 |
Why?
| | gamma-Glutamyltransferase | 1 | 2004 | 3 | 0.270 |
Why?
| | Cholestasis | 1 | 2004 | 9 | 0.260 |
Why?
| | Alkaline Phosphatase | 1 | 2004 | 16 | 0.260 |
Why?
| | Academic Medical Centers | 1 | 2005 | 158 | 0.260 |
Why?
| | Hepatitis C Antibodies | 1 | 2003 | 6 | 0.260 |
Why?
| | Cyclosporine | 1 | 2003 | 19 | 0.250 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2014 | 512 | 0.240 |
Why?
| | Internship and Residency | 2 | 2016 | 201 | 0.240 |
Why?
| | United States Food and Drug Administration | 2 | 2016 | 75 | 0.240 |
Why?
| | Pyrrolidines | 2 | 2019 | 21 | 0.230 |
Why?
| | Follow-Up Studies | 5 | 2014 | 2028 | 0.210 |
Why?
| | Kidney Failure, Chronic | 1 | 2002 | 176 | 0.200 |
Why?
| | Molecular Conformation | 1 | 2019 | 18 | 0.190 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 117 | 0.190 |
Why?
| | Isoindoles | 2 | 2015 | 2 | 0.190 |
Why?
| | Predictive Value of Tests | 2 | 2013 | 637 | 0.180 |
Why?
| | Carbamates | 2 | 2016 | 12 | 0.170 |
Why?
| | Retrospective Studies | 4 | 2014 | 3591 | 0.160 |
Why?
| | Double-Blind Method | 4 | 2014 | 559 | 0.160 |
Why?
| | Counterfeit Drugs | 1 | 2016 | 2 | 0.160 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 8 | 0.160 |
Why?
| | Commerce | 1 | 2016 | 12 | 0.150 |
Why?
| | Canada | 1 | 2016 | 57 | 0.150 |
Why?
| | Fraud | 1 | 2016 | 15 | 0.150 |
Why?
| | Quality Control | 1 | 2016 | 50 | 0.150 |
Why?
| | Quinolines | 1 | 2016 | 18 | 0.150 |
Why?
| | Safety | 1 | 2016 | 59 | 0.150 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2016 | 29 | 0.150 |
Why?
| | Retinoids | 1 | 2016 | 6 | 0.150 |
Why?
| | Carotenoids | 1 | 2016 | 15 | 0.150 |
Why?
| | Isoquinolines | 1 | 2016 | 16 | 0.150 |
Why?
| | New Zealand | 1 | 2015 | 14 | 0.150 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2016 | 71 | 0.150 |
Why?
| | Australia | 1 | 2015 | 50 | 0.150 |
Why?
| | Actins | 1 | 2016 | 63 | 0.150 |
Why?
| | Europe | 1 | 2015 | 88 | 0.150 |
Why?
| | Deoxycytidine | 1 | 2015 | 43 | 0.150 |
Why?
| | Carrier Proteins | 1 | 2016 | 129 | 0.140 |
Why?
| | Imidazoles | 1 | 2016 | 74 | 0.140 |
Why?
| | Uridine Monophosphate | 1 | 2015 | 2 | 0.140 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2015 | 15 | 0.140 |
Why?
| | Odds Ratio | 1 | 2016 | 327 | 0.140 |
Why?
| | Uracil | 1 | 2014 | 5 | 0.130 |
Why?
| | Macrocyclic Compounds | 1 | 2014 | 5 | 0.130 |
Why?
| | Anilides | 1 | 2014 | 11 | 0.130 |
Why?
| | Phenotype | 1 | 2015 | 379 | 0.130 |
Why?
| | Education, Medical, Graduate | 1 | 2015 | 83 | 0.130 |
Why?
| | Biopsy | 4 | 2016 | 283 | 0.130 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 153 | 0.120 |
Why?
| | Health Care Costs | 1 | 2014 | 81 | 0.120 |
Why?
| | Terminology as Topic | 1 | 2012 | 52 | 0.120 |
Why?
| | Nucleosides | 1 | 2012 | 3 | 0.110 |
Why?
| | Immunoassay | 1 | 2012 | 45 | 0.110 |
Why?
| | Immunity, Cellular | 1 | 2012 | 68 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 40 | 0.110 |
Why?
| | Genetic Testing | 1 | 2012 | 73 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 163 | 0.100 |
Why?
| | Hepatitis B virus | 1 | 2010 | 7 | 0.100 |
Why?
| | Molecular Epidemiology | 1 | 2010 | 29 | 0.100 |
Why?
| | Patient Selection | 1 | 2012 | 264 | 0.100 |
Why?
| | Global Health | 1 | 2010 | 60 | 0.100 |
Why?
| | Risk Factors | 3 | 2012 | 2664 | 0.100 |
Why?
| | Fatty Liver | 1 | 2009 | 40 | 0.090 |
Why?
| | Prognosis | 1 | 2012 | 1028 | 0.090 |
Why?
| | Graft Survival | 1 | 2008 | 111 | 0.090 |
Why?
| | Aged | 5 | 2014 | 10295 | 0.090 |
Why?
| | Hemoglobins | 1 | 2008 | 81 | 0.080 |
Why?
| | Secondary Prevention | 1 | 2007 | 67 | 0.080 |
Why?
| | Biomedical Research | 1 | 2008 | 89 | 0.080 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 239 | 0.080 |
Why?
| | RNA | 1 | 2006 | 36 | 0.080 |
Why?
| | Pilot Projects | 2 | 2008 | 455 | 0.070 |
Why?
| | Internal Medicine | 2 | 2016 | 34 | 0.070 |
Why?
| | Mutation | 1 | 2008 | 464 | 0.070 |
Why?
| | Sample Size | 1 | 2005 | 26 | 0.070 |
Why?
| | Health Expenditures | 1 | 2005 | 20 | 0.070 |
Why?
| | Valine | 2 | 2016 | 13 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 389 | 0.070 |
Why?
| | Hepatitis | 1 | 2004 | 9 | 0.070 |
Why?
| | Curriculum | 2 | 2016 | 158 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2012 | 1083 | 0.070 |
Why?
| | International Cooperation | 2 | 2016 | 38 | 0.070 |
Why?
| | Autoantibodies | 1 | 2004 | 119 | 0.060 |
Why?
| | Viral Vaccines | 1 | 2003 | 2 | 0.060 |
Why?
| | Cross Reactions | 1 | 2003 | 28 | 0.060 |
Why?
| | Viral Envelope Proteins | 1 | 2003 | 24 | 0.060 |
Why?
| | Viral Proteins | 1 | 2003 | 30 | 0.060 |
Why?
| | Living Donors | 1 | 2003 | 16 | 0.060 |
Why?
| | Research Design | 1 | 2005 | 238 | 0.060 |
Why?
| | Sampling Studies | 1 | 2003 | 32 | 0.060 |
Why?
| | Injections, Subcutaneous | 1 | 2003 | 41 | 0.060 |
Why?
| | Drug Resistance | 1 | 2003 | 68 | 0.060 |
Why?
| | Probability | 1 | 2003 | 104 | 0.060 |
Why?
| | Databases, Factual | 1 | 2005 | 391 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 156 | 0.060 |
Why?
| | Alanine Transaminase | 2 | 2016 | 24 | 0.060 |
Why?
| | Immunoglobulin G | 1 | 2003 | 134 | 0.060 |
Why?
| | Prospective Studies | 1 | 2008 | 1934 | 0.060 |
Why?
| | Sialoglycoproteins | 1 | 2002 | 9 | 0.060 |
Why?
| | General Surgery | 1 | 2003 | 61 | 0.060 |
Why?
| | Attitude of Health Personnel | 1 | 2003 | 181 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2002 | 687 | 0.050 |
Why?
| | Cohort Studies | 1 | 2005 | 2014 | 0.050 |
Why?
| | Viremia | 2 | 2012 | 36 | 0.040 |
Why?
| | Career Choice | 1 | 2016 | 33 | 0.040 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2016 | 1 | 0.040 |
Why?
| | Isoprostanes | 1 | 2016 | 2 | 0.040 |
Why?
| | Lipid Peroxidation | 1 | 2016 | 10 | 0.040 |
Why?
| | beta Carotene | 1 | 2016 | 14 | 0.040 |
Why?
| | Vitamin A | 1 | 2016 | 8 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2016 | 43 | 0.040 |
Why?
| | Diterpenes | 1 | 2016 | 10 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2016 | 22 | 0.040 |
Why?
| | Hepatic Stellate Cells | 1 | 2016 | 11 | 0.040 |
Why?
| | Adolescent | 2 | 2014 | 2667 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 148 | 0.040 |
Why?
| | Young Adult | 2 | 2014 | 2277 | 0.040 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 41 | 0.040 |
Why?
| | Risk | 1 | 2016 | 228 | 0.040 |
Why?
| | Hospitals, University | 1 | 2015 | 46 | 0.040 |
Why?
| | Needs Assessment | 1 | 2015 | 50 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2016 | 140 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2014 | 3 | 0.030 |
Why?
| | Drug Carriers | 1 | 2014 | 8 | 0.030 |
Why?
| | Liver Neoplasms | 1 | 2016 | 117 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2016 | 494 | 0.030 |
Why?
| | 2-Naphthylamine | 1 | 2014 | 4 | 0.030 |
Why?
| | Drug Combinations | 1 | 2014 | 88 | 0.030 |
Why?
| | Chronic Disease | 1 | 2016 | 544 | 0.030 |
Why?
| | Clinical Competence | 1 | 2016 | 274 | 0.030 |
Why?
| | Animals | 1 | 2003 | 5312 | 0.030 |
Why?
| | Limit of Detection | 1 | 2012 | 4 | 0.030 |
Why?
| | Disease Progression | 1 | 2016 | 861 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 986 | 0.030 |
Why?
| | Endpoint Determination | 1 | 2012 | 31 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2016 | 1240 | 0.030 |
Why?
| | Sex Factors | 1 | 2012 | 542 | 0.030 |
Why?
| | Age Factors | 1 | 2012 | 943 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2009 | 20 | 0.020 |
Why?
| | Triglycerides | 1 | 2009 | 50 | 0.020 |
Why?
| | Cholesterol | 1 | 2009 | 68 | 0.020 |
Why?
| | Illinois | 1 | 2004 | 266 | 0.020 |
Why?
| | Public Opinion | 1 | 2003 | 6 | 0.020 |
Why?
| | Ethics, Medical | 1 | 2003 | 17 | 0.020 |
Why?
| | Data Collection | 1 | 2003 | 120 | 0.010 |
Why?
| | Prevalence | 1 | 2004 | 544 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2002 | 16 | 0.010 |
Why?
| | Recurrence | 1 | 2003 | 389 | 0.010 |
Why?
| | Drug Resistance, Viral | 1 | 2002 | 43 | 0.010 |
Why?
| | Health Services Accessibility | 1 | 2003 | 113 | 0.010 |
Why?
|
|
Jensen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|